Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Calcium-Sensing Receptor Autoantibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1: Epitopes, Specificity, Functional Affinity, IgG Subclass, and Effects on Receptor Activity.

Habibullah M, Porter JA, Kluger N, Ranki A, Krohn KJE, Brandi ML, Brown EM, Weetman AP, Kemp EH.

J Immunol. 2018 Dec 1;201(11):3175-3183. doi: 10.4049/jimmunol.1701527. Epub 2018 Oct 31.

2.

Immunosuppressive therapy of autoimmune hypoparathyroidism in a patient with activating autoantibodies against the calcium-sensing receptor.

Chamberlin M, Kemp EH, Weetman AP, Khadka B, Brown EM.

Clin Endocrinol (Oxf). 2019 Jan;90(1):214-221. doi: 10.1111/cen.13886. Epub 2018 Nov 14.

PMID:
30358904
3.

Severe Symptomatic Hypocalcemia from HIV Related Hypoparathyroidism.

Sandhu S, Desai A, Batra M, Girdhar R, Chatterjee K, Kemp EH, Makdissi A, Chaudhuri A.

Case Rep Endocrinol. 2018 Sep 25;2018:8270936. doi: 10.1155/2018/8270936. eCollection 2018.

4.

Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies.

Piranavan P, Li Y, Brown E, Kemp EH, Trivedi N.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):550-556. doi: 10.1210/jc.2018-01151.

PMID:
30252069
5.

Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial.

Teulings HE, Tjin EPM, Willemsen KJ, van der Kleij S, Ter Meulen S, Kemp EH, Krebbers G, van Noesel CJM, Franken CLMC, Drijfhout JW, Melief CJM, Nieuweboer-Krobotova L, Nieweg OE, van der Hage JA, van der Veen JPW, Relyveld GN, Luiten RM.

Oncoimmunology. 2018 Jan 15;7(4):e1419113. doi: 10.1080/2162402X.2017.1419113. eCollection 2018.

6.

Alteration of Immune-Mechanisms by Human Microbiota and Development and Prevention of Human Diseases.

Dwivedi M, Ansarullah, Radichev I, Kemp EH.

J Immunol Res. 2017;2017:6985256. doi: 10.1155/2017/6985256. Epub 2017 Dec 28. No abstract available.

7.

Autoantibodies against the calcium-sensing receptor and cytokines in autoimmune polyglandular syndromes types 2, 3 and 4.

Kemp EH, Kahaly GJ, Porter JA, Frommer L, Weetman AP.

Clin Endocrinol (Oxf). 2018 Jan;88(1):139-145. doi: 10.1111/cen.13482. Epub 2017 Oct 3.

8.

Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants.

Jin Y, Andersen G, Yorgov D, Ferrara TM, Ben S, Brownson KM, Holland PJ, Birlea SA, Siebert J, Hartmann A, Lienert A, van Geel N, Lambert J, Luiten RM, Wolkerstorfer A, Wietze van der Veen JP, Bennett DC, Taïeb A, Ezzedine K, Kemp EH, Gawkrodger DJ, Weetman AP, Kõks S, Prans E, Kingo K, Karelson M, Wallace MR, McCormack WT, Overbeck A, Moretti S, Colucci R, Picardo M, Silverberg NB, Olsson M, Valle Y, Korobko I, Böhm M, Lim HW, Hamzavi I, Zhou L, Mi QS, Fain PR, Santorico SA, Spritz RA.

Nat Genet. 2016 Nov;48(11):1418-1424. doi: 10.1038/ng.3680. Epub 2016 Oct 10.

9.

Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway.

Astor MC, Løvås K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebø BG, Svartberg J, Husebye ES.

J Clin Endocrinol Metab. 2016 Aug;101(8):3045-53. doi: 10.1210/jc.2016-1477. Epub 2016 May 17.

10.

Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity.

Dwivedi M, Kumar P, Laddha NC, Kemp EH.

Autoimmun Rev. 2016 Apr;15(4):379-92. doi: 10.1016/j.autrev.2016.01.002. Epub 2016 Jan 7. Review.

11.

Early-onset hypoparathyroidism and chronic keratitis revealing APECED.

Mezgueldi E, Bertholet-Thomas A, Milazzo S, Morris M, Bacchetta J, Fabien N, Cochat P, Weetman AP, Kemp EH, Belot A.

Clin Case Rep. 2015 Oct;3(10):809-13. doi: 10.1002/ccr3.354. Epub 2015 Aug 26.

12.

Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to systemic lupus erythematosus in an Indian population.

Pradhan V, Kemp EH, Nadkar M, Rajadhyaksha A, Lokhandwala K, Patwardhan M, Weetman AP, Nadkarni A, Ghosh K.

Scand J Rheumatol. 2015;44(5):425-7. doi: 10.3109/03009742.2015.1022214. No abstract available.

13.

Tumour necrosis factor-α antagonists as therapies for vitiligo.

Kemp EH.

Br J Dermatol. 2015 Sep;173(3):635. doi: 10.1111/bjd.14057. No abstract available.

14.
15.

Serological proteome analysis reveals new specific biases in the IgM and IgG autoantibody repertoires in autoimmune polyendocrine syndrome type 1.

Dubucquoi S, Proust-Lemoine E, Kemp EH, Ryndak A, Lefèvre-Dutoit V, Bellart M, Saugier-Véber P, Duban-Deweer S, Wémeau JL, Prin L, Lefranc D.

Autoimmunity. 2015;48(8):532-41. doi: 10.3109/08916934.2015.1077230. Epub 2015 Aug 27.

16.

Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases.

Oftedal BE, Hellesen A, Erichsen MM, Bratland E, Vardi A, Perheentupa J, Kemp EH, Fiskerstrand T, Viken MK, Weetman AP, Fleishman SJ, Banka S, Newman WG, Sewell WA, Sozaeva LS, Zayats T, Haugarvoll K, Orlova EM, Haavik J, Johansson S, Knappskog PM, Løvås K, Wolff AS, Abramson J, Husebye ES.

Immunity. 2015 Jun 16;42(6):1185-96. doi: 10.1016/j.immuni.2015.04.021.

17.

IL-14 and IL-16 are expressed in the thyroid of patients with either Graves' disease or Hashimoto's thyroiditis.

Kemp EH, Ajjan RA, Metcalfe RA, Watson PF, Weetman AP.

Clin Endocrinol (Oxf). 2015 Nov;83(5):726-32. doi: 10.1111/cen.12810. Epub 2015 Jun 1.

18.

PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity.

Mathieu AL, Verronese E, Rice GI, Fouyssac F, Bertrand Y, Picard C, Chansel M, Walter JE, Notarangelo LD, Butte MJ, Nadeau KC, Csomos K, Chen DJ, Chen K, Delgado A, Rigal C, Bardin C, Schuetz C, Moshous D, Reumaux H, Plenat F, Phan A, Zabot MT, Balme B, Viel S, Bienvenu J, Cochat P, van der Burg M, Caux C, Kemp EH, Rouvet I, Malcus C, Méritet JF, Lim A, Crow YJ, Fabien N, Ménétrier-Caux C, De Villartay JP, Walzer T, Belot A.

J Allergy Clin Immunol. 2015 Jun;135(6):1578-88.e5. doi: 10.1016/j.jaci.2015.01.040. Epub 2015 Apr 2.

19.

Programmed death 1 expressing regulatory T cells in vitiligo.

Kemp EH.

Br J Dermatol. 2015 Apr;172(4):847-8. doi: 10.1111/bjd.13595. No abstract available.

20.

Antithyroid hormone autoantibodies in vitiligo.

Kemp EH.

Br J Dermatol. 2014 Oct;171(4):690. doi: 10.1111/bjd.13317. No abstract available.

PMID:
25319423
21.

Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics.

Dwivedi M, Kemp EH, Laddha NC, Mansuri MS, Weetman AP, Begum R.

Autoimmun Rev. 2015 Jan;14(1):49-56. Review.

22.

The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.

Teulings HE, Willemsen KJ, Glykofridis I, Krebbers G, Komen L, Kroon MW, Kemp EH, Wolkerstorfer A, van der Veen JP, Luiten RM, Tjin EP.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1086-96. doi: 10.1111/pcmr.12294. Epub 2014 Aug 4.

PMID:
25043574
23.

Prevalence and clinical associations of calcium-sensing receptor and NALP5 autoantibodies in Finnish APECED patients.

Kemp EH, Habibullah M, Kluger N, Ranki A, Sandhu HK, Krohn KJ, Weetman AP.

J Clin Endocrinol Metab. 2014 Mar;99(3):1064-71. doi: 10.1210/jc.2013-3723. Epub 2013 Jan 1.

PMID:
24423312
24.

Acquired hypocalciuric hypercalcemia in a patient with CKD.

Kuo E, Kemp EH, Sandhu HK, Brown EM, Weetman AP, Huang CL.

Am J Kidney Dis. 2013 Dec;62(6):1151-4. doi: 10.1053/j.ajkd.2013.04.023. Epub 2013 Jun 27.

PMID:
23810542
25.

A redundant role of human thyroid peroxidase propeptide for cellular, enzymatic, and immunological activity.

Godlewska M, Góra M, Buckle AM, Porebski BT, Kemp EH, Sutton BJ, Czarnocka B, Banga JP.

Thyroid. 2014 Feb;24(2):371-82. doi: 10.1089/thy.2013.0127. Epub 2013 Sep 26.

26.

Graves' disease, hypoparathyroidism, systemic lupus erythematosus, alopecia, and angioedema: autoimmune polyglandular syndrome variant or coincidence?

Melcescu E, Kemp EH, Majithia V, Vijayakumar V, Uwaifo GI, Koch CA.

Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):217-22.

PMID:
23527724
27.

Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis.

Teulings HE, Tjin EP, Willemsen KJ, Krebbers G, van Noesel CJ, Kemp EH, Nieuweboer-Krobotova L, van der Veen JP, Luiten RM.

Br J Dermatol. 2013 Apr;168(4):733-8. doi: 10.1111/bjd.12136. Epub 2013 Feb 27.

PMID:
23421690
28.

Low frequency of pendrin autoantibodies detected using a radioligand binding assay in patients with autoimmune thyroid disease.

Kemp EH, Sandhu HK, Watson PF, Weetman AP.

J Clin Endocrinol Metab. 2013 Feb;98(2):E309-13. doi: 10.1210/jc.2012-3683. Epub 2013 Jan 15.

PMID:
23322815
29.

The angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian patients with vitiligo: a case-control study and meta-analysis.

Patwardhan M, Pradhan V, Taylor LH, Thakkar V, Kharkar V, Khopkar U, Ghosh K, Gawkrodger DJ, Teare MD, Weetman AP, Kemp EH.

Br J Dermatol. 2013 Jun;168(6):1195-204. doi: 10.1111/bjd.12177.

PMID:
23278772
30.

Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo.

Jin Y, Birlea SA, Fain PR, Ferrara TM, Ben S, Riccardi SL, Cole JB, Gowan K, Holland PJ, Bennett DC, Luiten RM, Wolkerstorfer A, van der Veen JP, Hartmann A, Eichner S, Schuler G, van Geel N, Lambert J, Kemp EH, Gawkrodger DJ, Weetman AP, Taïeb A, Jouary T, Ezzedine K, Wallace MR, McCormack WT, Picardo M, Leone G, Overbeck A, Silverberg NB, Spritz RA.

Nat Genet. 2012 May 6;44(6):676-80. doi: 10.1038/ng.2272.

31.

Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo.

Kroon MW, Kemp EH, Wind BS, Krebbers G, Bos JD, Gawkrodger DJ, Wolkerstorfer A, van der Veen JP, Luiten RM.

J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1172-5. doi: 10.1111/j.1468-3083.2012.04501.x. Epub 2012 Mar 10.

PMID:
22404127
32.

Epitopes, avidity and IgG subclasses of tyrosine hydroxylase autoantibodies in vitiligo and alopecia areata patients.

Rahoma SF, Sandhu HK, McDonagh AJ, Gawkrodger DJ, Weetman AP, Kemp EH.

Br J Dermatol. 2012 Jul;167(1):17-28. doi: 10.1111/j.1365-2133.2012.10889.x. Epub 2012 May 14.

PMID:
22329856
33.

Vitiligo patients from India (Mumbai) show differences in clinical, demographic and autoantibody profiles compared to patients in western countries.

Pradhan V, Patwardhan M, Thakkar V, Kharkar V, Khopkar U, Ghosh K, Weetman AP, Gawkrodger DJ, Kemp EH.

J Eur Acad Dermatol Venereol. 2013 Mar;27(3):279-86. doi: 10.1111/j.1468-3083.2011.04367.x. Epub 2011 Nov 28.

PMID:
22122088
34.

Demonstration of autoantibodies against tyrosine hydroxylase in patients with alopecia areata.

Kemp EH, Sandhu HK, Weetman AP, McDonagh AJ.

Br J Dermatol. 2011 Dec;165(6):1236-43. doi: 10.1111/j.1365-2133.2011.10597.x. Epub 2011 Nov 17.

PMID:
21895622
35.

First report of anti-calcium-sensing receptor antibodies in a patient with Sjogren's syndrome and primary hypoparathyroidism.

Harris HE, Kemp EH, Brown EM, Weetman AP, Swaminathan K.

Rheumatology (Oxford). 2011 Jun;50(6):1173-5. doi: 10.1093/rheumatology/ker128. Epub 2011 Mar 30. No abstract available.

PMID:
21454310
36.

Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset.

Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, Bennett DC, Herbstman DM, Wallace MR, McCormack WT, Kemp EH, Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taïeb A, Jouary T, Ezzedine K, van Geel N, Lambert J, Overbeck A, Spritz RA.

J Invest Dermatol. 2011 Jun;131(6):1308-12. doi: 10.1038/jid.2011.12. Epub 2011 Feb 17.

37.

Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor.

Pallais JC, Kemp EH, Bergwitz C, Kantham L, Slovik DM, Weetman AP, Brown EM.

J Clin Endocrinol Metab. 2011 Mar;96(3):672-80. doi: 10.1210/jc.2010-1739. Epub 2010 Dec 15.

38.

Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo.

Kemp EH, Emhemad S, Akhtar S, Watson PF, Gawkrodger DJ, Weetman AP.

Exp Dermatol. 2011 Jan;20(1):35-40. doi: 10.1111/j.1600-0625.2010.01181.x.

PMID:
21158937
39.

Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP.

Birlea SA, Jin Y, Bennett DC, Herbstman DM, Wallace MR, McCormack WT, Kemp EH, Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taïeb A, Jouary T, Ezzedine K, van Geel N, Lambert J, Overbeck A, Fain PR, Spritz RA.

J Invest Dermatol. 2011 Feb;131(2):371-81. doi: 10.1038/jid.2010.337. Epub 2010 Nov 18.

40.

Development of a 3D human in vitro skin co-culture model for detecting irritants in real-time.

Cantòn I, Cole DM, Kemp EH, Watson PF, Chunthapong J, Ryan AJ, MacNeil S, Haycock JW.

Biotechnol Bioeng. 2010 Aug 1;106(5):794-803. doi: 10.1002/bit.22742.

PMID:
20564616
41.

Common variants in FOXP1 are associated with generalized vitiligo.

Jin Y, Birlea SA, Fain PR, Mailloux CM, Riccardi SL, Gowan K, Holland PJ, Bennett DC, Wallace MR, McCormack WT, Kemp EH, Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taïeb A, Jouary T, Ezzedine K, van Geel N, Lambert J, Overbeck A, Spritz RA.

Nat Genet. 2010 Jul;42(7):576-8. doi: 10.1038/ng.602. Epub 2010 Jun 6.

42.

Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.

Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, Mailloux CM, Sufit AJ, Hutton SM, Amadi-Myers A, Bennett DC, Wallace MR, McCormack WT, Kemp EH, Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taïeb A, Jouary T, Ezzedine K, van Geel N, Lambert J, Overbeck A, Spritz RA.

N Engl J Med. 2010 May 6;362(18):1686-97. doi: 10.1056/NEJMoa0908547. Epub 2010 Apr 21.

43.

Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1.

Kemp EH, Gavalas NG, Krohn KJ, Brown EM, Watson PF, Weetman AP.

J Clin Endocrinol Metab. 2009 Dec;94(12):4749-56. doi: 10.1210/jc.2009-1080. Epub 2009 Oct 16.

44.

Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library.

Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP, Kemp EH.

J Invest Dermatol. 2010 Jan;130(1):230-40. doi: 10.1038/jid.2009.207.

45.

Mapping of human autoantibody binding sites on the calcium-sensing receptor.

Kemp EH, Gavalas NG, Akhtar S, Krohn KJ, Pallais JC, Brown EM, Watson PF, Weetman AP.

J Bone Miner Res. 2010 Jan;25(1):132-40. doi: 10.1359/jbmr.090703.

46.

Melanin-concentrating hormone and melanin-concentrating hormone receptors in mammalian skin physiopathology.

Kemp EH, Weetman AP.

Peptides. 2009 Nov;30(11):2071-5. doi: 10.1016/j.peptides.2009.04.025. Epub 2009 May 13. Review.

PMID:
19442695
47.

Mapping of melanin-concentrating hormone receptor 1 B cell epitopes predicts two major binding sites for vitiligo patient autoantibodies.

Gavalas NG, Gottumukkala RV, Gawkrodger DJ, Watson PF, Weetman AP, Kemp EH.

Exp Dermatol. 2009 May;18(5):454-63. doi: 10.1111/j.1600-0625.2008.00813.x. Epub 2009 Mar 6.

PMID:
19320743
48.

Vitiligo following a combined liver-kidney transplant.

Bradley V, Kemp EH, Dickinson C, Key T, Gibbs P, Clatworthy MR.

Nephrol Dial Transplant. 2009 Feb;24(2):686-8. doi: 10.1093/ndt/gfn661. Epub 2008 Nov 28.

PMID:
19042928
49.

Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease.

Skinningsrud B, Husebye ES, Gervin K, Løvås K, Blomhoff A, Wolff AB, Kemp EH, Egeland T, Undlien DE.

Eur J Hum Genet. 2008 Aug;16(8):977-82. doi: 10.1038/ejhg.2008.33. Epub 2008 Feb 27.

50.

Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?

Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, Kemp EH, Giachino C, Liu JB, Luiten RM, Lambe T, Le Poole IC, Dammak I, Onay H, Zmijewski MA, Dell'Anna ML, Zeegers MP, Cornall RJ, Paus R, Ortonne JP, Westerhof W.

Exp Dermatol. 2008 Feb;17(2):139-40; discussion 141-60. doi: 10.1111/j.1600-0625.2007.00666_1.x.

PMID:
18205713

Supplemental Content

Support Center